Financials data is unavailable for this security.
View more
Year on year Benitec Biopharma Inc 's net income fell 7.44% from a loss of 18.21m to a larger loss of 19.56m despite relatively flat revenues.
Gross margin | 1,542.86% |
---|---|
Net profit margin | -309,885.70% |
Operating margin | -307,028.60% |
Return on assets | -186.85% |
---|---|
Return on equity | -267.59% |
Return on investment | -260.89% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Benitec Biopharma Inc fell by 1.59m. Cash Flow from Financing totalled 16.02m or 21,353.33% of revenues. In addition the company used 18.01m for operations while cash used for investing totalled 1.00k.
Cash flow per share | -9.61 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.22 |
---|---|
Tangible book value per share | 4.22 |
More ▼
Balance sheet in USDView more
Current ratio | 4.18 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 62.73%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 59.77 |